Conversion to Advagraf + conversion of non-immunosuppressant drugs to once daily + Conversion to once daily MPA
Pre-clinicalActive 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
End-Stage Renal Disease
Conditions
End-Stage Renal Disease
Trial Timeline
Apr 1, 2016 → Dec 1, 2024
NCT ID
NCT02426502About Conversion to Advagraf + conversion of non-immunosuppressant drugs to once daily + Conversion to once daily MPA
Conversion to Advagraf + conversion of non-immunosuppressant drugs to once daily + Conversion to once daily MPA is a pre-clinical stage product being developed by Astellas Pharma for End-Stage Renal Disease. The current trial status is active. This product is registered under clinical trial identifier NCT02426502. Target conditions include End-Stage Renal Disease.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02426502 | Pre-clinical | Active |
Competing Products
20 competing products in End-Stage Renal Disease